Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2020-07-06 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a monthly update (as of June 30, 2020) detailing the total number of shares and voting rights. This type of mandatory periodic disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific announcement related to share capital changes, but given the options, it most closely aligns with a mandatory regulatory disclosure that isn't a standard financial report (10-K, IR, ER). Since it details the composition of the share capital and voting rights, it is a specific type of regulatory update. While 'SHA' (Share Issue/Capital Change) is related, this is a routine monthly disclosure of the *current* total, not an announcement of a *change* or *issue*. The closest fit among the provided codes for a mandatory, periodic disclosure about share capital structure, especially when referencing AMF rules, is often captured under general regulatory filings or specific capital structure notifications. Given the content is purely about the total number of shares and voting rights, it is a specific capital structure notification. However, none of the codes perfectly match 'Monthly Voting Rights Disclosure'. Comparing the options: It is not an ER, IR, 10-K, or CT. It is a regulatory announcement. Since it deals directly with the number of shares and voting rights, it is a form of capital structure update. If we must choose the most specific fit, 'SHA' (Share Issue/Capital Change) is related to capital structure, but 'MRQ' (Major Shareholding Notification) is about changes in ownership thresholds, which is different. Given the French context and the nature of the disclosure (total capital structure), it is a mandatory regulatory filing. If a specific code for voting rights disclosure existed, it would be used. In the absence of a perfect match, and recognizing it as a mandatory regulatory disclosure concerning capital structure, 'SHA' is the closest category related to the underlying subject matter (shares/capital), or 'RNS' as a general regulatory filing. Since the document explicitly details the total number of shares and voting rights, which is a fundamental aspect of the share capital, 'SHA' (Share Issue/Capital Change) is a plausible, though imperfect, fit for a capital structure update. However, these monthly voting rights disclosures are often treated as general regulatory announcements. Let's re-evaluate based on the definitions. It is not a dividend (DIV), director dealing (DIRS), or management change (MANG). It is a formal regulatory communication. Since it is a formal, periodic disclosure mandated by regulators, and doesn't fit the specific financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS), 'RNS' (Regulatory Filings - general fallback) is the safest classification for a mandatory, non-standard report disclosure. Alternatively, because it reports the total number of shares, which underpins capital structure, 'SHA' might be intended. Given the precision required, and the fact that this is a routine monthly report on the *total* capital base, 'RNS' is the most appropriate fallback for a specific regulatory filing that lacks its own dedicated code among the primary options. I will select RNS as the general regulatory filing category for this specific French capital disclosure.
2020-07-06 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "2020 : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT" (2020: SEMI-ANNUAL REPORT OF THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT BROKERAGE FIRM). It explicitly states the status of the liquidity contract as of June 30, 2020, and details the transactions (purchases and sales) executed during the first semester (1H) of 2020. This type of periodic disclosure regarding market making or liquidity provision activities is a specific regulatory requirement, often related to share capital management or market transparency. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on comprehensive financial statements. Since it details the activity of a specific financial arrangement over a defined period (six months), it fits best under a category related to capital/financing updates or a specific regulatory disclosure. Given the options, it is a report detailing the activity related to the company's share structure/market support, which aligns closely with Capital/Financing Update (CAP) or, due to its specific nature as a periodic report on a financial arrangement, it could be considered a specialized regulatory filing. However, since it is a detailed report on the status of a liquidity contract, it is most accurately classified as a Capital/Financing Update (CAP) as it directly relates to the management of the company's shares in the market, or potentially a Regulatory Filing (RNS) if no better fit exists. Given the detailed transactional data provided, it is more substantive than a simple announcement. Comparing it to the definitions, 'CAP' (Capital/Financing Update) covers financing activities and capital structure changes, which includes managing share liquidity. It is a report, not just an announcement of a report. I will classify it as CAP.
2020-07-02 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces significant regulatory feedback from the US FDA regarding the design of a Phase III trial (NANORAY-312) and the Chemistry, Manufacturing, and Controls (CMC) development plan for a future New Drug Application (NDA) for the product NBTXR3. This type of announcement, detailing clinical trial progress, regulatory milestones, and strategic updates, is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it focuses on key operational and regulatory achievements rather than a full financial report (10-K or IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these press releases often accompany or precede formal earnings reports to highlight major operational news. It is not a formal financial statement, a proxy filing, or a management discussion and analysis. FY 2020
2020-06-17 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces significant regulatory and clinical development updates regarding the drug NBTXR3, specifically receiving feedback from the FDA for advancing a Phase III study (NANORAY-312) and agreement on the Chemistry, Manufacturing, and Controls (CMC) plan for a future New Drug Application (NDA). This type of announcement, detailing clinical progress, regulatory milestones, and strategic updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release detailing key operational and regulatory achievements rather than just a brief notification of a report's publication (RPA), and it contains substantial information about clinical trials and regulatory interactions, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally as a Regulatory Filing (RNS) for non-standard regulatory news. Given the content focuses heavily on FDA feedback and trial progression, which often accompanies or substitutes for formal quarterly/annual reporting highlights, ER is a strong candidate. However, since it is a specific announcement about regulatory feedback and trial design rather than a summary of financial performance for a period, RNS (Regulatory Filings - the general category for miscellaneous regulatory announcements) is the most appropriate fit, as it is a formal communication of a regulatory event. Upon review of the definitions, 'ER' is for initial announcement of periodical financial results (key highlights only). This document is about clinical/regulatory progress, not financial results highlights. 'RNS' is the fallback for miscellaneous filings. This document is a press release detailing FDA feedback and trial advancement, which is a type of regulatory/operational update that doesn't fit the other specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS). Therefore, RNS is the most suitable classification.
2020-06-17 French
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly announces the company's "CHIFFRE D'AFFAIRES DU PREMIER TRIMESTRE 2020" (First Quarter 2020 Revenue). It provides key financial highlights (revenue figures for Q1 2020 vs Q1 2019, cash position) and operational updates, but it is not the comprehensive quarterly report itself (which would be an 'IR' or '10-Q' equivalent). This format, focusing on initial results announcement, perfectly matches the definition of an Earnings Release (ER). The document also mentions the next financial communication date, confirming its nature as a periodic results announcement. Q1 2020
2020-04-30 French
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 99% confidence The document is explicitly titled "*PRESS RELEASE*" and announces the company's "FIRST QUARTER 2020 REVENUES". It provides unaudited revenue figures for Q1 2020 compared to Q1 2019, along with operational updates. This format—a press release summarizing key financial metrics for a specific period shorter than a year (Q1)—is the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general announcement of a report being published (RPA). Q1 2020
2020-04-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.